6:34 Blythe: Okay, so once you've nailed the diagnosis, the real magic happens in how you approach treatment. The new ACP guidelines completely flip the traditional approach on its head, and honestly, it's about time.
6:48 Miles: You mean how they're prioritizing economic evidence and patient preferences over just clinical effectiveness? Because that's a major shift from how we usually think about guidelines.
0:26 Blythe: Exactly! So here's what they found: when they looked at all these migraine prevention medications—beta-blockers, antidepressants, anti-seizure meds, the newer CGRP inhibitors—there really weren't clinically meaningful differences in effectiveness between most of them. They were all helping people, just not dramatically better than each other.
7:17 Miles: Right, so instead of saying "this drug is best," they're saying "these drugs work similarly, so let's consider cost and what patients actually want." And the cost differences are staggering—we're talking about median annual costs of $67 for amitriptyline versus potentially over $20,000 for some of the CGRP monoclonal antibodies.
7:36 Blythe: That's a 300-fold difference! And when you factor in that patients generally prefer oral medications over injectables—which the guidelines document with moderate-certainty evidence—it really shapes your first-line approach.
7:49 Miles: So their Recommendation 1 makes perfect sense: start with a beta-blocker like metoprolol or propranolol, the anti-seizure medication valproate, the SNRI venlafaxine, or the tricyclic amitriptyline. These are your workhorses—effective, affordable, oral.
8:05 Blythe: And I love how they provide specific dosing frameworks. For propranolol, you start at 20 mg twice daily, increase by 40 mg per week, targeting 40-120 mg twice daily. For amitriptyline, start at 10 mg at bedtime, increase by 10 mg weekly, targeting 10-100 mg at bedtime. It's not guesswork anymore.
8:27 Miles: The guidelines also give you decision-making frameworks for choosing between these first-line options. If your patient has depression, anxiety, insomnia, or concurrent tension-type headache, lean toward amitriptyline or nortriptyline. If they have asthma, avoid the beta-blockers. If they're overweight, consider topiramate, though it's actually listed as third-line due to side effect concerns.
8:48 Blythe: That brings us to Recommendation 2, which is where the newer medications come in. If patients don't tolerate or don't respond adequately to those first-line treatments, then you move to CGRP antagonists—either the gepants like atogepant or rimegepant, or the monoclonal antibodies like erenumab, fremanezumab, galcanezumab, or eptinezumab.
9:11 Miles: What's interesting is they're not saying these newer drugs don't work—they clearly do. But the evidence shows they're not dramatically more effective than the older options, and they cost dramatically more. So you're essentially paying a premium for potentially better tolerability and convenience.
9:26 Blythe: And that's where patient preference really matters. Some people will gladly pay more for a monthly injection they can self-administer versus daily pills that might cause side effects. Others will prioritize the lower cost. The key is having that conversation upfront.
9:42 Miles: The guidelines emphasize using "an informed decision-making approach" that discusses benefits, harms, costs, patient values and preferences including financial burden and mode of administration, contraindications, pregnancy status, and comorbidities. It's truly personalized medicine.
9:59 Blythe: Then Recommendation 3 addresses topiramate as a third-line option. It can be effective—they found some evidence it reduces migraine frequency—but it has more side effects compared to beta-blockers and CGRP inhibitors. So you reserve it for people who've tried first and second-line options without success.
10:18 Miles: The acute treatment side is where things get really practical for primary care. The guidelines are clear about this stepwise approach: first-line is ibuprofen 400 mg, aspirin 1000 mg, naproxen sodium 500-550 mg, or acetaminophen 1000 mg.
10:36 Blythe: And if that's not cutting it, you move to second-line triptans. They list all of them with specific dosing—sumatriptan 100 mg, rizatriptan 10 mg, almotriptan 12.5 mg. Plus they give you formulation guidance: subcutaneous sumatriptan if the patient is vomiting early, oral wafers if fluid worsens nausea, nasal sprays if they're nauseated.
11:00 Miles: Third-line is combination therapy—naproxen sodium with a triptan. And fourth-line is fixed-dose combination analgesics, though they note these aren't recommended for routine use. What I appreciate is they're giving you a clear escalation pathway.
11:14 Blythe: The antiemetic piece is crucial too. Domperidone 10 mg or metoclopramide 10 mg for nausea. Because migraine isn't just about head pain—it's about the whole constellation of symptoms that make people miserable.
11:30 Miles: For tension-type headache, the approach is simpler but follows the same logic. Acute treatment is ibuprofen, aspirin, naproxen, or acetaminophen. Prevention is first-line amitriptyline or nortriptyline, second-line mirtazapine or venlafaxine.
11:46 Blythe: And then there's medication overuse headache, which is this huge problem that primary care needs to recognize and manage. The definition is clear: triptans, ergots, combination analgesics, or opioids on 10 or more days per month, or acetaminophen or NSAIDs on 15 or more days per month.
12:06 Miles: The management approach is systematic: patient education about how overuse increases headache frequency, a withdrawal strategy—abrupt for simple analgesics and triptans, gradual for opioids—plus starting a prophylactic medication and having a plan for treating severe breakthrough headaches with frequency limits.